City

Harbin (1)

Tianjin (1)

Xiamen (1)

Condition

Neuroendocrine Tumor Grade 3 (3)

Neuroendocrine Carcinoma (2)

Neuroendocrine Neoplasm (1)

Neuroendocrine Tumors (1)

Pancreatic Carcinoma (1)

Overall Status

Recruiting (2)

Not yet recruiting (1)

Sign in for free

Phase

phase 2 (2)

Sponsor

Peking Union Medical College Hospital (1)

Qilu Hospital of Shandong University (1)

Tianjin Medical University Cancer Institute and Hospital (1)

Collaborator

Harbin Medical University (1)

Shandong Provincial Hospital Affiliated to Shandong First Medical University (1)

The Affiliated Hospital of Qingdao University (1)

The First Affiliated Hospital of Xiamen University (1)

Weifang People's Hospital (1)

Yantai Yuhuangding Hospital (1)

Intervention

sintilimab (2)

surufatinib (2)

chidamide (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Other (3)

Study Type

Interventional (2)

Observational (1)

neuroendocrine tumor grade 3

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Surufatinib in G3 Neuroendocrine Tumors

Not yet recruiting

Neuroendocrine Tumor Grade 3

Surufatinib

(no location specified)

Aug 2, 2023

Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma, Pancreatic Carcinoma Trial in Tianjin (Surufatinib, Sintilimab)

Recruiting

Neuroendocrine Tumor Grade 3
+2 more

Tianjin, Tianjin, China

Rui Liu

Nov 17, 2022

Neuroendocrine Tumors, Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma Trial in Xiamen, Harbin (Chidamide, Sintilimab)

Recruiting

Neuroendocrine Tumors
+3 more

Xiamen, Fujian, China
+1 more

Nov 22, 2021